Who are NAABAK eyedrops's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OZODROP, LiquiTears, Tears Naturale II Ophthalmic Solution, OTX-101 0.09%, SJP-0035 0.001%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naabak-eyedrops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

NAABAK eyedrops — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NAABAK eyedrops (NAABAK eyedrops) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ophthalmic solution. Area: Ophthalmology.

marketed Ophthalmic solution Ocular inflammation and discomfort Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

NAABAK eyedrops (NAABAK eyedrops) — Laboratoires Thea.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NAABAK eyedrops TARGET	NAABAK eyedrops	Laboratoires Thea	marketed	Ophthalmic solution	Ocular inflammation and discomfort
OZODROP	OZODROP	University of Molise	marketed	Ozone therapy / Ophthalmic solution
LiquiTears	LiquiTears	Chakshu Research, Inc.	marketed	Artificial tear / Lubricating ophthalmic solution
Tears Naturale II Ophthalmic Solution	Tears Naturale II Ophthalmic Solution	ORA, Inc.	marketed	Artificial tear / Lubricating ophthalmic solution
OTX-101 0.09%	OTX-101 0.09%	Sun Pharmaceutical Industries Limited	phase 3	ophthalmic solution
SJP-0035 0.001%	SJP-0035 0.001%	Senju Pharmaceutical Co., Ltd.	phase 3	Topical ophthalmic solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ophthalmic solution class)

Laboratoires Thea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NAABAK eyedrops — Competitive Intelligence Brief. https://druglandscape.com/ci/naabak-eyedrops. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab